The Biopharmaceutics Classification System: Recent Applications in Pharmaceutical Discovery, Development, and Regulation

Oral Drug Absorption: Prediction and Assessment, Second Edition

Volumn , Issue , 2016, Pages 138-154

  Sheng, Jennifer J ^a   Amidon, Gordon L ^b  

^a ASTRAZENECA   (United Kingdom)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84862199075     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.3109/9781420077346-9     Document Type: Chapter

References (78)

1. Amidon GL, Lennernas H, Shah VP, et al. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995; 12(3):413-420.
2. CDER/FDA. Guidance for Industry, Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. August 2000. Available at: http://www.fda. gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070124.pdf
3. CPMP E. Note for guidance on investigation of bioavailability and bioequivalence. 2001.
4. CDER/FDA. Guidance for Industry, Immediate Release Solid Oral Dosage Forms:Scale-up and Post Approval Changes. 1995. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070636.pdf
5. CDER/FDA. Guidance for Industry, Dissolution Testing of Immediate Release Solid Oral Dosage Forms. August 1997. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070237.pdf
6. WHO EC. WHO expert committee on specifications for pharmaceutical preparations. Fortieth report. World Health Organization, 2006:1-461.
7. Yu LX, Amidon GL, Polli JE, et al. Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm Res 2002; 19(7):921-925.
8. Yu LX, Carlin AS, Amidon GL, et al. Feasibility studies of utilizing disk intrinsic dissolution rate to classify drugs. Int J Pharm 2004; 270(1-2):221-227.
9. Kim JS, Mitchell S, Kijek P, et al. The suitability of an in situ perfusion model for permeability determinations: utility for BCS class I biowaiver requests. Mol Pharm 2006; 3(6):686-694.
10. Benet LZ, Amidon GL, Barends DM, et al. The use of BDDCS in classifying the permeability of marketed drugs. Pharm Res 2008; 25(3):483-488.
11. Wu CY, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 2005; 22(1):11-23.
12. Polli JE, Abrahamsson B, Yu LX, et al. Summary workshop report: bioequivalence, biopharmaceutics classification system, and beyond. AAPS J 2008; 93(6):1375-1381.
13. Nicolaides E, Symillides M, Dressman JB, et al. Biorelevant dissolution testing to predict the plasma profile of lipophilic drugs after oral administration. Pharm Res 2001; 18(3):380-388.
14. Eddington ND, Rekhi GS, Lesko LJ, et al. Scale-up effects on dissolution and bioavailability of propranolol hydrochloride and metoprolol tartrate tablet formulations. AAPS PharmSciTech 2000; 1(2):E14.
15. Yu LX. Conference communication. In: AAPS Workshop on BE, BCS, and Beyond. North Bethesda, MD: AAPS, FDA, 2007.
16. Zareba G. Pregabalin: a new agent for the treatment of neuropathic pain. Drugs Today (Barc) 2005; 41(8):509-516.
17. Cook J. BCS-based biowaiver: case study 1. Pregabalin. In: AAPS Workshop on BE, BCS, and Beyond. North Bethesda, MD: AAPS, FDA, 2007.
18. Addicks WJ. BCS-based biowaiver: case study 4. Applications of the biopharmaceutical classification system at a generic pharmaceutical company. In: AAPS Workshop on BE, BCS, and Beyond. North Bethesda, MD: AAPS, FDA, 2007.
19. Alt A, Potthast H, Moessinger J, et al. Biopharmaceutical characterization of sotalolcontaining oral immediate release drug products. Eur J Pharm Biopharm 2004; 58(1):145-150.
20. Graffner C. Regulatory aspects of drug dissolution from a European perspective. Eur J Pharm Sci 2006; 29(3-4):288-293.
21. Frick A, Moller H, Wirbitzki E. Biopharmaceutical characterization of oral immediate release drug products. In vitro/in vivo comparison of phenoxymethylpenicillin potassium, glimepiride and levofloxacin. Eur J Pharm Biopharm 1998; 46(3):305-311.
22. Lennernas H, Gjellan K, Hallgren R, et al. The influence of caprate on rectal absorption of phenoxymethylpenicillin: experience from an in-vivo perfusion in humans. J Pharm Pharmacol 2002; 54(4):499-508.
23. Vogt M, Derendorf H, Kramer J, et al. Biowaiver monographs for immediate release solid oral dosage forms: prednisone. J Pharm Sci 2007; 96(6):1480-1489.
24. Kalantzi L, Reppas C, Dressman JB, et al. Biowaiver monographs for immediate release solid oral dosage forms: acetaminophen (paracetamol). J Pharm Sci 2006; 95(1):4-14.
25. Pilbrant A, Schannong M, Vessman J. Pharmacokinetics and bioavailability of tranexamic acid. Eur J Clin Pharmacol 1981; 20(1):65-72.
26. Yu LX, Straughn AB, Faustino PJ, et al. The effect of food on the relative bioavailability of rapidly dissolving immediate-release solid oral products containing highly soluble drugs. Mol Pharm 2004; 1(5):357-362.
27. Gu CH, Li H, Levons J, et al. Predicting effect of food on extent of drug absorption based on physicochemical properties. Pharm Res 2007; 24(6):1118-1130.
28. McEvoy GK, ed. AHFS 2007 Drug Information. Bethesda: American Society of Health-System Pharmacists, Inc., 2007.
29. Oda M, Saitoh H, Kobayashi M, et al. Beta-cyclodextrin as a suitable solubilizing agent for in situ absorption study of poorly water-soluble drugs. Int J Pharm 2004; 280 (1-2):95-102.
30. Barr WH, Lin CC, Radwanski E, et al. The pharmacokinetics of ceftibuten in humans. Diagn Microbiol Infect Dis 1991; 14(1):93-100.
31. Svensson CK, Cumella JC, Tronolone M, et al. Effects of hydralazine, nitroglycerin, and food on estimated hepatic blood flow. Clin Pharmacol Ther 1985; 37(4):464-468.
32. Shepherd AM, Irvine NA, Ludden TM. Effect of food on blood hydralazine levels and response in hypertension. Clin Pharmacol Ther 1984; 36(1):14-18.
33. Kasim NA, Whitehouse M, Ramachandran C, et al. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharm 2004; 1(1):85-96.
34. Yazdanian M, Briggs K, Jankovsky C, et al. The “high solubility” definition of the current FDA guidance on biopharmaceutical classification system may be too strict for acidic drugs. Pharm Res 2004; 21(2):293-299.
35. Polli JE, Yu LX, Cook JA, et al. Summary workshop report: biopharmaceutics classification system-implementation challenges and extension opportunities. J Pharm Sci 2004; 93(6):1375-1381.
36. Alvan G, Orme M, Bertilsson L, et al. Pharmacokinetics of indomethacin. Clin Pharmacol Ther 1975; 18(3):364-373.
37. Oberbauer R, Krivanek P, Turnheim K. Pharmacokinetics of indomethacin in the elderly. Clin Pharmacokinet 1993; 24(5):428-434.
38. Jung D, Mroszczak E, Bynum L. Pharmacokinetics of ketorolac tromethamine in humans after intravenous, intramuscular, and oral administration. Eur J Clin Pharmacol 1988; 35(4):423-425.
39. Nievel JG, Havard CW, Mitchell P, et al. Effect of meal size and composition on the bioavailability of ketoprofen (Oruvail). Xenobiotica 1987; 17(4):487-492.
40. Stiegler S, Birkel M, Jost V, et al. Pharmacokinetics and relative bioavailability after single dose administration of 25 mg ketoprofen solution as compared to tablets. Methods Find Exp Clin Pharmacol 1995; 17(2):129-134.
41. WHO. Proposal to waive in vivo bioequivalence requirements for the WHO model list of essential medicines immediate release, solid oral dosage forms. In: World Health Organization, ed. QAS/04.109/Rev1. Geneva, Switzerland: WHO, 2005.
42. WHO. Multisource (Generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability. In: World Health Organization, ed. QAS/04.093/Rev.4. Geneva, Switzerland: WHO, 2005.
43. Jantratid E, Prakongpan S, Amidon GL, et al. Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine. Clin Pharmacokinet 2006; 45(4):385-399.
44. Koch KM, Parr AF, Tomlinson JJ, et al. Effect of sodium acid pyrophosphate on ranitidine bioavailability and gastrointestinal transit time. Pharm Res 1993; 10(7):1027-1030.
45. Polli JE. In vitro studies are sometimes better than conventional human BE studies in assessing equivalence. In: AAPS Workshop on BE, BCS, and Beyond. North Bethesda, MD, USA: AAPS, FDA, May 2007.
46. Buice RG, Subramanian VS, Duchin KL, et al. Bioequivalence of a highly variable drug: an experience with nadolol. Pharm Res 1996; 13(7):1109-1115.
47. Stella VJ, Nti-Addae KW. Prodrug strategies to overcome poor water solubility. Adv Drug Deliv Rev 2007; 59(7):677-694.
48. Hemenway JN, Nti-Addae K, Guarino VR, et al. Preparation, characterization, and in vivo conversion of new water-soluble sulfenamide prodrugs of carbamazepine. Bioorg Med Chem Lett 2007; 17(23):6629-6632.
49. Venkatesh S, Lipper RA. Role of the development scientist in compound lead selection and optimization. J Pharm Sci 2000; 89(2):145-154.
50. Neervannan S. Preclinical formulations for discovery and toxicology: physicochemical challenges. Expert Opin Drug Metab Toxicol 2006; 2(5):715-731.
51. Amidon GE, He X, Hageman MJ. Physicochemical characterization and principles of oral dosage form selection. In: Abraham Donald J, ed. Burger’s Medicinal Chemistry and Drug Discovery. 6th ed. Hoboken, NJ, USA: John Wiley and Sons, 2003.
52. Lennernas H, Abrahamsson B. The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension. J Pharm Pharmacol 2005; 57(3):273-385.
53. Beaumont K, Webster R, Gardner I, et al. Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: challenges to the discovery scientist. Curr Drug Metab 2003; 4(6):461-485.
54. Ettmayer P, Amidon GL, Clement B, et al. Lessons learned from marketed and investigational prodrugs. J Med Chem 2004; 47(10):2393-2404.
55. Landowski CP, Sun D, Foster DR, et al. Gene expression in the human intestine and correlation with oral valacyclovir pharmacokinetic parameters. J Pharmacol Exp Ther 2003; 306(2):778-786.
56. Beauchamp LM, Krenitsky TA, Orr GF. Amino acid ester prodrugs of acyclovir. Antiviral Chem Chemother 1992; 3:157-164.
57. Han H, de Vrueh RL, Rhie JK, et al. 50-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm Res 1998; 15(8):1154-1159.
58. Salama NN, Eddington ND, Fasano A. Tight junction modulation and its relationship to drug delivery. Adv Drug Deliv Rev 2006; 58(1):15-28.
59. Aungst BJ. Intestinal permeation enhancers. J Pharm Sci 2000; 89(4):429-442.
60. CDER/FDA. Guidance for Industry, Food-Effect Bioavailability, and Fed Bioequivalence Studies. December 2002. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070241.pdf
61. Fleisher D, Li C, Zhou Y, et al. Drug, meal, and formulation interactions influencing drug absorption after oral administration. Clinical implications. Clin Pharmacokinet 1999; 36(3):233-254.
62. Carver PL, Fleisher D, Zhou SY, et al. Meal composition effects on the oral bioavailability of indinavir in HIV-infected patients. Pharm Res 1999; 16(5):718-724.
63. Granneman GR, Mukherjee D. The effect of food on the bioavailability of temafloxacin. A review of 3 studies. Clin Pharmacokinet 1992; 22(suppl 1):48-56.
64. Yu LX. An integrated model for determining causes of poor oral drug absorption. Pharm Res 1999; 16(12):1883-1887.
65. Jinno J, Oh D, Crison JR, et al. Dissolution of ionizable water-insoluble drugs: the combined effect of pH and surfactant. J Pharm Sci 2000; 89(2):268-274.
66. Sheng JJ, Kasim NA, Chandrasekharan R, et al. Solubilization and dissolution of insoluble weak acid, ketoprofen: effects of pH combined with surfactant. Eur J Pharm Sci 2006; 29(3-4):306-314.
67. Lindahl A, Ungell AL, Knutson L, et al. Characterization of fluids from the stomach and proximal jejunum in men and women. Pharm Res 1997; 14(4):497-502.
68. Perez de la Cruz Moreno M, Oth M, Deferme S, et al. Characterization of fasted-state human intestinal fluids collected from duodenum and jejunum. J Pharm Pharmacol 2006; 58(8):1079-1089.
69. Kalantzi L, Goumas K, Kalioras V, et al. Characterization of the human upper gastrointestinal contents under conditions simulating bioavailability/bioequivalence studies. Pharm Res 2006; 23(1):165-176.
70. Yeh KC, Deutsch PJ, Haddix H, et al. Single-dose pharmacokinetics of indinavir and the effect of food. Antimicrob Agents Chemother 1998; 42(2):332-338.
71. Van Peer A, Woestenborghs R, Heykants J, et al. The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects. Eur J Clin Pharmacol 1989; 36(4):423-426.
72. Zimmermann T, Yeates RA, Laufen H, et al. Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole, and fluconazole. Eur J Clin Pharmacol 1994; 46(2):147-150
73. Li C, Fleisher D, Li L, et al. Regional-dependent intestinal absorption and meal composition effects on systemic availability of LY303366, a lipopeptide antifungal agent, in dogs. J Pharm Sci 2001; 90(1):47-57.
74. Nguyen TV, Fleisher D, Smith DE. In vivo effects of glycyl-glutamate and glycylsarcosine on gabapentin oral absorption in rat. Pharm Res 2007; 24(8):1538-1543.
75. Nguyen TV, Smith DE, Fleisher D. PEPT1 enhances the uptake of gabapentin via trans-stimulation of b0, + exchange. Pharm Res 2007; 24(2):353-360.
76. Dickinson P, Abrahamsson BS. Clinical relevance of dissolution testing in quality by design. In: AAPS Workshop on BE, BCS, and Beyond. North Bethesda, MD, USA:AAPS, FDA, 2007.
77. Takagi T, Ramachandran C, Bermejo M, et al. A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan. Mol Pharm 2006; 3(6):631-643.
78. Kim YH, Ramachandran C, Crippen GM, et al. In silico approaches to prediction of permeability, solubility, and BCS class: provisional classification of the top-selling immediate-release oral drug products in the United States, Great Britain, Spain, and South Korea (to be submitted).